Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Specifically targeting ERK1 or ERK2 kills Melanoma cells

25 Jan 2012

Abstract excerpt

BACKGROUND: Overcoming the notorious apoptotic resistance of melanoma cells remains a therapeutic challenge given dismal survival of patients with metastatic melanoma. However, recent clinical trials using a BRAF inhibitor revealed encouraging results for patients with advanced BRAF mutant bearing melanoma, but drug resistance accompanied by recovery of phospho-ERK (pERK) activity present challenges for this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cutaneous Melanoma Detection and Management
Share to melanin and skin pigmentation
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22277029
DOI: 10.1186/1479-5876-10-15

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 21 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Specifically targeting ERK1 or ERK2 kills Melanoma cellsPMID 22277029Read ↗

RAF-Mutant Melanomas Differentially Depend on ERK2 Over ERK1 to Support Aberrant MAPK Pathway Activation and Cell Proliferation.Semantic proximity Read ↗

Targeting RAS/RAF/MEK/ERK signaling in metastatic melanomaSemantic proximity Read ↗

Non-BRAF targeted therapies for melanoma: protein kinase inhibitors in Phase II clinical trials.Semantic proximity Read ↗

Identification of Aurora Kinase B and Wee1-Like Protein Kinase as Downstream Targets of V600EB-RAF in MelanomaSemantic proximity Read ↗

Analysis of BRAF inhibitor resistance in melanoma cellsSemantic proximity Read ↗

Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinaseSemantic proximity Read ↗

The MEK/ERK Network as a Therapeutic Target in Human CancerSemantic proximity Read ↗

A Progressive Review of V600E-B-RAF-Dependent Melanoma and Drugs Inhibiting It.Semantic proximity Read ↗

Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.Semantic proximity Read ↗

Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.Semantic proximity Read ↗

Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitorsSemantic proximity Read ↗

Revisiting the Role of B-RAF Kinase as a Therapeutic Target in Melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.